On January 11, the traditional Chinese medicine sector fluctuated upward, and the industry generally showed a continuous positive trend

【Pharmaceutical Network Pharmaceutical Stock Market】 Benefiting from a good policy environment, with the improvement of residents' consumption level and the continuous strengthening of health and wellness awareness, the scale of the traditional Chinese medicine industry continues to expand, and the industry as a whole continues to show a good trend
.
On January 11, the traditional Chinese medicine sector fluctuated to the upside, with Huasen Pharmaceutical rising by more than 5%, and Zhongsheng Pharmaceutical, Tongrentang, Taiji Group, Kangyuan Pharmaceutical, Yiling Pharmaceutical, etc.
following suit
.
On January 11, Huasen Pharmaceutical rose in the afternoon, rising once to 5.
88%, and the current market value is 9 billion yuan
.
It is reported that Huasen Pharmaceutical said in an institutional survey today that the market demand for virus-related drugs has increased significantly, and the number of orders for related varieties has surged
.
The exclusive variety of sweet orange ice plum flakes has been in short supply, and the current production capacity has shown a state
of stage saturation.
Now that there is another XBB strain that causes abdominal pain and diarrhea in the lower digestive tract, experts have recommended our painstaking granules, so orders for pains granules have surged
significantly recently.
In order to ensure the supply of related products to meet market demand and solve the problem of capacity bottlenecks, Huasen Pharmaceutical has also done a lot of work
.
For example, the company quickly launched the reserve production line, restored the production qualification of recommended medicinal sweet orange ice plum tablets and Liuwei Anshen capsules in the original site, expanded the production scale to ensure supply, and carried out larger load and larger capacity production
.
At present, Huasen Pharmaceutical's sweet orange ice plum flakes have been produced at the original site, and the production capacity has increased by about 15%, which has a certain positive impact on the company's business performance in the short term, and it is expected that the production capacity of sweet orange ice plum flakes can be further increased by more than
40% through technological transformation.
On January 11, Zhongsheng Pharmaceutical rose 5% intraday, and as of 13:28, it was quoted at 28.
36 yuan, with a transaction of 1.
539 billion yuan and a turnover rate of 7.
89%.

It is reported that on January 9, Zhongsheng Pharmaceutical said on the investor interactive platform that the company's completed phase I clinical study suggested that RAY1216 has good safety, tolerability and pharmacokinetic properties
in healthy people.
RAY1216 tablets are used in a randomized, double-blind, placebo-controlled phase III clinical study for the treatment of patients with mild and common SARS-CoV-2 infection, and the enrollment of all cases has been completed according to the requirements of the clinical protocol
.
In addition, Zhongsheng Pharmaceutical said that the company holds the approval of coenzyme Q10 capsules, can carry out production and sales according to market conditions, and the company has the ability and mechanism to respond
quickly to market changes.
ZSP1273 tablets are currently in the phase III clinical research stage, and multiple clinical research centers have achieved case enrollment
.
On January 11, Tongrentang rose 5%
intraday.
As of 10:16, it was reported at 46.
57 yuan, with a transaction of 410 million yuan, and a turnover rate of 0.
66%.

It is reported that Tongrentang is mainly engaged in the production and sales of traditional Chinese proprietary medicines, and produces more than 400 specifications of proprietary Chinese medicines all year round, with rich product dosage forms, covering more than 20 product dosage forms
such as pills, powders, wines and capsules, oral liquids, and pill drops.
At present, Tongrentang has formed five major sectors with the pharmaceutical industry as the core and supported by health care, medical pension, commercial retail and international pharmaceutical industry in terms of business structure, and the seven sub-groups are Tongrentang Shares, Tongrentang Technology, Tongrentang Health, Tongrentang Medical Care, Tongrentang Commerce, Tongrentang Chinese Medicine and Tongrentang Medicinal Materials Ginseng Investment
.
On January 11, Taiji Group also rose
rapidly intraday.
It is reported that the two strategic main products of Taiji Group, Huo Xiang Zhengqi Liquid and Rush Syrup, through category breaking, to achieve crowd breaking circle, track breaking circle, and functional breaking circle, greatly improving product premium ability and brand power
.
Recently, Taiji Group disclosed the third quarter report of 2022, focusing on the company's quarterly financial data, and a number of performance indicators have achieved significant growth
.
According to the announcement, Taiji Group achieved revenue of 3.
358 billion yuan in the third quarter, a year-on-year increase of 7.
41%; The gross profit margin increased to 45.
24%, and the product price and cost structure improved; Net profit deducted from non-attributable parent was 139 million yuan, a year-on-year increase of 1327%, a significant improvement for three consecutive quarters; The total revenue in the first three quarters was 10.
544 billion yuan
.
Kangyuan Pharmaceutical, which is following today's rise, announced on January 10 that the company recently received the "Drug Clinical Trial Approval Notice" for KYS202002A injection issued by the National Medical Products Administration, agreeing to carry out clinical trials
of relapsed and refractory multiple myeloma.
KYS202002A is a fully human anti-CD38 monoclonal antibody
developed by Kangyuan Pharmaceutical.
In addition, Yiling Pharmaceutical, which rose today, data shows that since the same period in 2020, the three-year compound growth rate of Yiling Pharmaceutical's stock price has reached 34.
77%.

The industry said that the steady rise in the stock price is a concentrated reflection
of Ling Pharmaceutical's achievements in products, performance and research and development, and the continuous improvement of the company's basic market.
For example, in terms of products, Yiling Pharmaceutical has developed a series of traditional Chinese medicines
with independent intellectual property rights around six categories of diseases with high cardiovascular and cerebrovascular diseases, diabetes, respiratory, tumor, neurological and urinary diseases, and large market dosage.
At present, Yiling Pharmaceutical has 13 new drugs, of which 8 are listed in the national medical insurance catalogue and 5 are listed in the national essential drug list, which provides an important driving force
for the company's performance growth.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.